Topics:
Hematologic Malignancies • Pediatric Oncology • Medical Oncology • Non-Hodgkin Lymphoma • AYA
Should targeted therapies such as Brentuximab or Crizotinib be used in the upfront management of anaplastic large cell lymphoma in a pediatric or AYA patient?
Answer from: at Community Practice
Good question. Importantly, I am assuming that the question is for ALK+ patients who have systemic disease because ALK inhibitors have no role in ALK- disease and cutaneous only ALCL is really an entirely different entity.In fact, the question is the primary aim of COG trial ANHL12P1 which uses eith...
Sign in or Register to read more